01—Abstract
Summary
Summary of the 8-K filed April 2, 2026. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) furnished an 8-K on April 2, 2026 reporting preliminary, unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billiona as of March 31, 2026.
For the three months ended March 31, 2026, the company repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 millionb (excluding fees and commission). The filing states that the audit of financial statements for the fiscal year ended March 31, 2026 is ongoing and could change this information. The press release furnished under Item 7.01 announces a new seamless Phase 2b/3 potentially registrational trial of brepocitinib (Priovant) in lichen planopilaris (LPP), with first subjects enrolled in March 2026.
LPP is described as the fourth late-stage indication for brepocitinib, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The FDA granted Priority Review to the brepocitinib NDA for DM with a PDUFA target action date in the third quarter of calendar 2026.
The release also reports that Immunovant's two Phase 3 GO studies of batoclimab in active, moderate-to-severe thyroid eye disease failed to meet their primary endpoint of a 2mm proptosis responder rate at Week 24, with consistent safety and no new safety signals. Immunovant will review future batoclimab plans with partner HanAll Biopharma, and it is prioritizing IMVT-1402, with topline Graves' disease data expected in calendar 2027.
02—Key points
Key Highlights
- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026
- Repurchased 3,956,362 common shares for approximately $109.7 million (excluding fees and commission) in the three months ended March 31, 2026
- Immunovant's two Phase 3 batoclimab studies in thyroid eye disease failed to meet the primary endpoint of ≥2mm proptosis responder rate at Week 24
- No new safety signals identified in the batoclimab TED studies; results consistent with previous findings
- Priovant initiating a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, its fourth late-stage indication, with first subjects enrolled in March 2026
- FDA granted Priority Review to brepocitinib NDA for dermatomyositis with PDUFA target date in Q3 calendar 2026
- Immunovant prioritizing IMVT-1402 in Graves' disease, with topline registrational data expected in calendar 2027
03—Questions
Frequently Asked Questions
How much cash and marketable securities does Roivant report?
Roivant announced preliminary, unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026. The filing notes the fiscal year-end audit is ongoing and could change this information.
How much stock did Roivant repurchase?
In the three months ended March 31, 2026, Roivant repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 million, excluding fees and commission.
Why did the batoclimab thyroid eye disease studies fail?
The two Phase 3 GO studies did not meet their primary endpoint of a ≥2mm proptosis responder rate at Week 24, based on the pre-specified statistical analysis plan. Patients showed greater proptosis improvement after the high-dose period than after the low-dose period, which the company says supports the benefit of deeper IgG suppression.
What is the status of brepocitinib in dermatomyositis and the new LPP program?
The FDA granted Priority Review to the brepocitinib NDA for dermatomyositis, with a PDUFA target action date in Q3 calendar 2026, and Priovant expects a DM launch in September. The new seamless Phase 2b/3 LPP trial enrolled its first subjects in March 2026. Topline Phase 3 data in NIU and Phase 3 initiation in CS are expected in the second half of calendar 2026.
What happens next with batoclimab and IMVT-1402?
Immunovant intends to review future batoclimab development plans with partner HanAll Biopharma and provide an update at a later date. It continues to advance IMVT-1402, an FcRn blocker, with topline data from potentially registrational Graves' disease studies expected in calendar 2027.
04—Continue